NASDAQ:ATRS Antares Pharma (ATRS) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free ATRS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$5.59▼$5.5950-Day Range$5.59▼$5.5952-Week Range$3.11▼$5.60Volume6 shsAverage Volume3.29 million shsMarket Capitalization$955.06 millionP/E Ratio23.29Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Antares Pharma alerts: Email Address Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About Antares Pharma Stock (NASDAQ:ATRS)Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.Read More Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", ATRS Stock News HeadlinesJanuary 24, 2024 | morningstar.comAntares Vision SpA AVDecember 7, 2023 | lse.co.ukAntares Vision Share Price (AV.MI)October 19, 2023 | markets.businessinsider.comAprea Therapeutics’ Promising Clinical Data and Distinctive Drug Profile: An Analysis of Jason McCarthy’s Buy RatingSeptember 3, 2023 | thestreet.comAntares Reaches New 52-Week High (AIS)August 2, 2023 | investing.comAntares Vision SpA (ANV)April 27, 2023 | marketwatch.comCOP Syringes Market Competitive Situation By 2030April 6, 2023 | marketwatch.comPharma Track and Trace Solutions Market Trends By 2031March 28, 2023 | marketwatch.comTransdermal Patch Drug Delivery System Market Size, Share, Demand, Opportunity, Outlook, Trends, Revenue, and Future Growth 2027March 27, 2023 | marketwatch.comDrug Transport Technology Market Top Players By 2031March 25, 2023 | marketwatch.comDrug Delivery Technology Market 2023 Size and Forecast to 2030March 4, 2023 | marketwatch.comPharma Track and Trace Solutions Market Forecast 2023 To 2029 Size, Global Predictive AnalyticsFebruary 17, 2023 | yahoo.comGlobal Genitourinary Drugs Market Report 2022 to 2027: Featuring Allergan, Antares Pharma, Bayer and Novartis Among OthersJanuary 4, 2023 | marketwatch.comPharma Track and Trace Solutions Market : Analysis, Forecast, Size, New Trends and Insights, Update, COVID-19 ImpactDecember 16, 2022 | marketwatch.comPharma Track and Trace Solutions Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028December 1, 2022 | marketwatch.comDrug Delivery Technology Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2030September 14, 2022 | yahoo.comPharmaceutical Drug Delivery Global Market Report 2022August 20, 2022 | marketwatch.comPharma Track and Trace Solutions Market Report Detailed Market Analysis and Forecasts 2022 To 2028 | 112 Pages ReportJune 8, 2022 | msn.comLooking Into Antares Pharma's Return On Invested CapitalMay 19, 2022 | seekingalpha.comHalozyme: Antares Pharma Bolsters Growth ProspectsMay 6, 2022 | finance.yahoo.comMiMedx Group and Inozyme Stock See Action From Activist InvestorsApril 26, 2022 | finance.yahoo.comHALOZYME COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF COMMON STOCK OF ANTARES PHARMAApril 14, 2022 | benzinga.comLooking Into Antares Pharma Inc's Recent Short InterestApril 14, 2022 | finance.yahoo.comAntares Pharma (ATRS) Moves 49.2% Higher: Will This Strength Last?April 13, 2022 | finance.yahoo.comAntares Pharma to be acquired by Halozyme in $960M dealApril 13, 2022 | investorplace.comWhy Is Antares Pharma (ATRS) Stock Up Today?See More Headlines Receive ATRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today6/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ATRS CUSIP03664210 CIK1016169 Webwww.antarespharma.com Phone(609) 359-3020Fax302-655-5049Employees201Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.24 Trailing P/E Ratio23.29 Forward P/E Ratio69.88 P/E GrowthN/ANet Income$46.29 million Net Margins21.90% Pretax Margin29.84% Return on Equity7.43% Return on Assets4.92% Debt Debt-to-Equity Ratio0.10 Current Ratio3.08 Quick Ratio2.87 Sales & Book Value Annual Sales$183.98 million Price / Sales5.19 Cash Flow$0.13 per share Price / Cash Flow43.89 Book Value$1.03 per share Price / Book5.43Miscellaneous Outstanding Shares170,852,000Free Float160,772,000Market Cap$955.06 million OptionableOptionable Beta1.15 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Robert F. Apple (Age 56)CEO, Pres & Director Comp: $1MMr. Fred M. Powell CPA (Age 61)Exec. VP & CFO Comp: $636.39kMr. Peter J. Graham Esq. (Age 55)Exec. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. Comp: $634.48kMr. Patrick MadsenSr. VP of OperationsMr. Keith Muckenhirn (Age 59)Principal Accounting Officer, VP of Fin. & Corp. Controller Ms. Tram BuiVP of Corp. Communications & Investor RelationsMr. Edward TykotSr. VP of Corp. Bus. Devel.Mr. Claude E. RichardsonSr. VP of HRDr. Peter Sadowski (Age 74)Sr. VP of Technology Portfolio & Intellectual Property Dr. Jonathan S. JaffeInterim EVP, Pharmaceutical R&D and Chief Medical OfficerMore ExecutivesKey CompetitorsIntersect ENTNASDAQ:XENTSeaSpineNASDAQ:SPNEAngioDynamicsNASDAQ:ANGOAccurayNASDAQ:ARAYCytosorbentsNASDAQ:CTSOView All Competitors ATRS Stock Analysis - Frequently Asked Questions How were Antares Pharma's earnings last quarter? Antares Pharma, Inc. (NASDAQ:ATRS) posted its quarterly earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, hitting analysts' consensus estimates of $0.03. The specialty pharmaceutical company had revenue of $48.19 million for the quarter, compared to analysts' expectations of $48.52 million. Antares Pharma had a trailing twelve-month return on equity of 7.43% and a net margin of 21.90%. During the same period in the previous year, the firm earned $0.03 EPS. What is Paul K. Wotton's approval rating as Antares Pharma's CEO? 5 employees have rated Antares Pharma Chief Executive Officer Paul K. Wotton on Glassdoor.com. Paul K. Wotton has an approval rating of 18% among the company's employees. This puts Paul K. Wotton in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Antares Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Conatus Pharmaceuticals (CNAT), Micron Technology (MU), Prospect Capital (PSEC), Gilead Sciences (GILD) and Sorrento Therapeutics (SRNE). This page (NASDAQ:ATRS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antares Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antares Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.